|
|
||||||||
1From the Institute of Human Genetics and the 2Department of Ophthalmology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany; the 3Azienda Ospedaliera di Monfalcone, Reparto di Oftalmologia, Monfalcone, Italy; and the 4Institute of Human Genetics, University of Regensburg, Regensburg, Germany.
| Abstract |
|---|
|
|
|---|
METHODS. The three LOXL1 single-nucleotide polymorphisms (SNPs), one intronic (rs2165241) and two nonsynonymous coding SNPs (rs1048661: R141L and rs3825942: G153D) were genotyped in a total of 726 unrelated patients with PEX or PEXG (517 Germans and 209 Italians) and 418 healthy subjects who had normal findings in repeated ophthalmic examinations, and a genetic association study was performed.
RESULTS. Strong association with the three LOXL1 common sequence variants was seen in both the PEX and PEXG patient groups independent of their geographic origin (rs2165241, combined OR = 3.42, P = 1.28 x 10–40; rs1048661, OR = 2.43, P = 2.90 x 10–19; and rs3825942, OR = 4.87, P = 8.22 x 10–23). Similarly, the common frequent haplotype (G-G) composed of the two coding SNPs (rs1048661 and rs3825942) was strongly associated in PEX and PEXG cohorts of both populations with the disease (combined OR = 3.58, P = 5.21x 10–43).
CONCLUSIONS. Genetic variants in LOXL1 confer risk to PEX in German and Italian populations, independent of the presence of secondary glaucoma, confirming findings in patients from Northern Europe.
The underlying disorder, PEX syndrome, is an age-related systemic disease of the extracellular matrix characterized by the multifocal production and progressive accumulation of a fibrillar extracellular material in intra- and extraocular tissues that is either the result of an excessive production or insufficient breakdown or both.4 Active involvement of the trabecular meshwork in this matrix process may lead to glaucoma development in about half of patients with PEX. Although its exact etiology and pathogenesis are still unknown, recent molecular biological and biochemical data support the pathogenetic concept of PEX syndrome as a type of stress-induced elastic microfibrillopathy, associated with the excessive production and abnormal aggregation of elastic microfibrils by a variety of potentially elastogenic cell types.5 6 Although a cause-and-effect relationship of PEX and other systemic diseases has not been established, increasing evidence suggests that PEX syndrome is associated with cardiovascular and cerebrovascular diseases.6 7
PEX syndrome occurs in all geographic regions worldwide, with reported prevalence rates averaging approximately 10% to 20% of the general population over age 60.8 Several lines of evidence show the tendency for the condition to cluster geographically and in certain racial or ethnic subgroups in difference prevalence,9 family aggregation and an increased risk of PEX in relatives of affected subjects suggest underlying genetic factors that predispose to this condition.10 11
Recently, a genome-wide association study detected three common SNPs on chromosome 15, area q24.1, in the lysyl oxidase-like 1 (LOXL1) gene, which is associated both with PEX and PEXG in Icelandic and Swedish populations.12 Strikingly, the results indicate that these gene polymorphisms are major susceptibility variants for PEX and support the notion that they confer risk of glaucoma mainly through PEX, as no association was observed in glaucoma patients only. Moreover, the disease-associated polymorphisms appeared to be present in virtually all patients with PEXG within the populations studied.12
The product of LOXL1 is a member of the lysyl oxidase (LO) protein family involved in the cross-linking of collagen and elastin in the extracellular space thereby stabilizing and insolubilizing polymeric elastin and collagen. It is required for elastic tissue homeostasis and is ubiquitously expressed.13 14 LOXL1-deficient mice showed reduced elastin content in different main organs and also had pelvic organ prolapse, enlarged airspaces of the lung, and skin and vascular abnormalities, but to our knowledge no eye phenotype was reported.15 Although LOXL1 is responsible for PEX in non-Scandinavian populations as well, its exact role in the pathogenesis of the disease remains to be determined.
Our study was designed to investigate association of three common LOXL1 polymorphisms with PEX and PEXG in two well-characterized patients cohorts originating from Germany and Italy.
| Methods |
|---|
|
|
|---|
The group of 726 patients with PEX consisted of 517 subjects of German and 209 subjects of Italian origin (European). Exact composition, age, and sex distribution data of the two different patients cohorts are reported below (Table 1) . No significance difference regarding age and sex distribution between the groups of patients was noted. All German individuals underwent standardized clinical examinations for PEX at the Ophthalmologic Department of the University of Erlangen-Nuremberg (Erlangen, Germany), whereas all Italian patients were examined at the Ophthalmologic Department of the Hospital in Monfalcone (Italy) with identical clinical examinations. Unequivocal agreement was found between the clinical investigators CYM in Germany and DP in Italy. All patients recruited with PEX syndrome had to have manifest PEX material on the anterior capsule and pupillary margin in mydriasis, clearly visible on slitlamp biomicroscopy. Secondary open-angle glaucoma due to PEX syndrome was defined, if elevated intraocular pressure (IOP), an open chamber angle, characteristic visual field defects in computed perimetry and characteristic glaucomatous disc atrophy were found in the presence of manifest PEX deposits on the anterior lens capsule and/or pupillary margin.
|
DNA Extraction and Genotyping
Genomic DNAs were extracted in the same laboratory from peripheral blood leukocytes of the 726 patients with PEX and 418 control individuals with automated techniques (AutoGenFlex 3000; AutoGen, Holliston, MA) using DNA chemistry (Flexigene; Qiagen, Hilden, Germany). SNP rs2165241 was genotyped with a predeveloped assay (TaqMan; Applied Biosystems [ABI], Foster City, CA). Reactions were prepared according to manufacturers instructions and performed on a sequence detection system (Prism 7900HT; ABI), by using standard thermal cycling conditions. The two nonsynonymous SNPs rs3825942 and rs1048661 were genotyped through direct sequencing as the corresponding assays failed. Purified PCR products (AMPure; Agencourt Bioscience, Beverly MA, purified on a Biomek NX96 platform; Beckman Instruments, Fullerton, CA) were sequenced using dye termination chemistry (Prism Fluorescent Dye Termination; ABI). Purified sequence reactions (CleanSEQ; Agencourt Bioscience) were resolved on a sequence analyzer (3730xl Sequence Analyzer; ABI) and analyzed with genome assembly software (SEQMAN software; DNAStar, Madison, WI). The average genotyping rate was 98.5%.
Statistical Analysis
Hardy-Weinberg equilibrium for all SNPs was confirmed in the case and control samples by using Haploview.16 Analysis of association by using allele counts and linkage disequilibrium-based haplotypes, was also performed with Haploview, which uses
2 statistics for assessing haplotype association (ver. 3.2).16 P < 0.05 was considered statistically significant. Odds ratio (OR) and 95% confidence interval (CI) were calculated with opensource software written by D. J. R. Hutchon (http://www.hutchon.net/ConfidOR.htm).17
| Results |
|---|
|
|
|---|
|
|
|
| Discussion |
|---|
|
|
|---|
The precise etiology and pathogenesis of PEX syndrome, however, remain poorly understood. Available immunohistochemical, biochemical, and molecular biological data strongly support the current concept that the fibrillar PEX deposits involve components of elastic fibers and microfibrils and that PEX syndrome is an elastic microfibrillopathy associated with an excessive production and aggregation of elastic microfibrils6 or with an abnormal regulation of elastin synthesis.7 20 21
The functional significance of LOXL1 in these PEX-associated elastotic processes is still unknown. To date apart from expression in lamina cribrosa cells and optic nerve head astrocytes,22 LOXL1 has been detected throughout the body in various organs, such as adult human lung, kidney, liver, heart, and muscle tissue,23 24 all of which are known to be affected by accumulations of PEX material.7 Recent studies have demonstrated that LOXL1 is specifically targeted to sites of elastogenesis by binding of the LOXL1 propeptide to both tropoelastine and fibulin-5 and that these interactions are essential for directing the deposition of the enzyme onto elastic fibers.14 The two risks coding SNPs (rs1048661 and rs382542) are located in the N-terminal part of pro-LOXL1 which was suggested to be critical in ensuring proper enzyme activation and in identifying the appropriate substrate that is to be acted on by the enzyme.14 15 As consequence these SNPs may influence targeting of pro-LOXL1 to tropoelastin or mediate the interaction of LOXL1 with other substrates.
Analyses of adipose tissues have shown that the expression of LOXL1 is decreased by 7.7% per risk allele of SNP rs1048661 (R141L),12 which is a small change, but in a late-onset disease it could be relevant. It is notable, however, that the risk allele G of rs3825942 (G153D), the variant that confers the greater risk in all population studies so far and interestingly the only one present in the Italian patient cohort, has no effect on LOXL1 expression, at least in adipose tissues. Nevertheless, inadequate levels of LOXL1 in systemic and ocular tissues could predispose to an impaired elastin homeostasis and elastotic processes. Alternatively, sequence variations in the LOXL1 propeptide may alter the substrate specificity of LOXL1 and may lead to abnormal cross-linking, aggregation and insolubilization of elastic microfibrillar components into the typical PEX fibers.
Further studies correlating the genetic variants in the LOXL1 and ocular tissue changes associated with PEX are now needed to confirm the association of SNPs rs1048661 and rs382542 with this condition and to elucidate its functional consequences.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication November 11, 2007; revised December 20, 2007; accepted February 15, 2008.
Disclosure: F. Pasutto, None; M. Krumbiegel, None; C.Y. Mardin, None; D. Paoli, None; R. Lämmer, None; B.H.F. Weber, None; F.E. Kruse, None; U. Schlötzer-Schrehardt, None; A. Reis, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: André Reis, Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Schwabachanlage 10, 91054 Erlangen, Germany; reis{at}humgenet.uni-erlangen.de.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Krumbiegel, F. Pasutto, C. Y. Mardin, N. Weisschuh, D. Paoli, E. Gramer, M. Zenkel, B. H. F. Weber, F. E. Kruse, U. Schlotzer-Schrehardt, et al. Exploring Functional Candidate Genes for Genetic Association in German Patients with Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma Invest. Ophthalmol. Vis. Sci., June 1, 2009; 50(6): 2796 - 2801. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Founti, F Topouzis, L van Koolwijk, C E Traverso, N Pfeiffer, and A C Viswanathan Biobanks and the importance of detailed phenotyping: a case study--the European Glaucoma Society GlaucoGENE project Br. J. Ophthalmol., May 1, 2009; 93(5): 577 - 581. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Trantow, M. Mao, G. E. Petersen, E. M. Alward, W. L. M. Alward, J. H. Fingert, and M. G. Anderson Lyst Mutation in Mice Recapitulates Iris Defects of Human Exfoliation Syndrome Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1205 - 1214. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Schlotzer-Schrehardt, F. Pasutto, P. Sommer, I. Hornstra, F. E. Kruse, G. O.H. Naumann, A. Reis, and M. Zenkel Genotype-Correlated Expression of Lysyl Oxidase-Like 1 in Ocular Tissues of Patients with Pseudoexfoliation Syndrome/Glaucoma and Normal Patients Am. J. Pathol., December 1, 2008; 173(6): 1724 - 1735. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |